MorphaBond Approval History
- FDA approved: Yes (First approved October 2nd, 2015)
- Brand name: MorphaBond
- Generic name: morphine sulfate
- Dosage form: Extended-Release Tablets
- Company: Inspirion Delivery Sciences, LLC
- Treatment for: Pain
MorphaBond (morphine sulfate) is an extended-release, abuse-deterrent, opioid analgesic for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
Morphine is a highly addictive substance, and extended-release morphine formulations containing larger doses are prone to abuse by a number of methods including oral consumption, intranasal insufflation, injection and smoking. MorphaBond is formulated with abuse-deterrent properties, providing the tablets with an increased resistance to cutting, crushing, or breaking. If the tablets are exposed to liquid, a viscous material is formed which is difficult to inject.
MorphaBond comes with a boxed warning to highlight the risks of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; and neonatal opioid withdrawal syndrome. MorphaBond tablets must be taken exactly as directed, as an overdose of morphine can be fatal.
MorphaBond tablets are administered twice a day, twelve hours apart. The tablets must be swallowed whole, and never crushed or chewed, to reduce the risk of overdose and death.
Common side effects of MorphaBond include constipation, dizziness, sedation, nausea, vomiting, sweating, dysphoria, and euphoric mood.
Development History and FDA Approval Process for MorphaBond
|Oct 5, 2015||FDA Approves MorphaBond (morphine sulfate) Extended-Release Tablets with Abuse-Deterrent Properties|
|Feb 9, 2015||Inspirion Delivery Technologies Announces FDA Acceptance of MorphaBond ER (morphine sulfate extended-release) NDA|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.